The Remission Rate of Type 2 Diabetes Outpatients with Premixed Insulin: The Result of a 5-Year Prospective Study

Abstract

The aim of the study was to evaluate the remission rate with short-term premixed insulin therapy in newly diagnosed type 2 diabetes outpatients and investigate predictors contributing to the remission rate. A 5-year prospective study was conducted with a total of 170 patients enrolled. Patients were treated with premixed insulin monotherapy or insulin in combination with one or two oral drugs. After glucose levels were well controlled, insulin and oral drugs were discontinued in a stepwise manner. The prolonged and partial remission rates were calculated and the possible factors contributing to remission were also analyzed. A total of 164 subjects completed the research study. The prolonged remission, partial remission and non-remission rates at the 5-year follow-up were 9.8, 59.8, and 30.5%, respectively. The remission rate was negatively correlated with disease duration (r=0.39). The combined rate of remission (prolonged and partial remission) significantly decreased when the duration was longer than 16 days, and reduced to approximately 50% after 1 month. Moreover, 75% of prolonged remission patients had duration of < 16 days. At the 5-year follow-up, the prolonged remission rate was 9.8% and the partial remission rate was 59.8%. Furthermore, the duration after diagnosis is an independent predictor of remission rate, and initiation of short-term premixed insulin therapy within the first 16 days of diabetes diagnosis is very important for remission. This is the first study to evaluate the remission rate associated with short-term premixed insulin therapy in recently diagnosed type 2 diabetes outpatients. At the 5-year follow-up, the prolonged remission rate was 9.8% and the partial remission rate was 59.8%. The duration of diabetes was identified as an independent predictor of drug-free remission. The initiation of short-term premixed insulin therapy within 15 days of diabetes onset is particular importance for remission.

Key words

type 2 diabetes - outpatients - short-term premixed insulin therapy - remission rates - prospective study

• References

• 1 Halban PA, Polonsky KS, Bowden DW. et al. beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014; 37: 1751-1758
• 2 Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218
• 3 Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet (London, England) 2011; 378: 169-181
• 4 Inzucchi SE, Bergenstal RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
• 5 Weng J, Li Y, Xu W. et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet (London, England) 2008; 371: 1753-1760
• 6 Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1: 28-34
• 7 Diabetes society of China Medical Association The prevention and therapy guideline in China type 2 diabetes (2017 edition). Chin J Pract Int Med 2018; 38: 292-344
• 8 Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract 2011; 65: 165-171
• 9 Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. MedGenMed 2007; 9: 12
• 10 Moghissi ES. Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes. Mount Sinai J Med New York 2008; 75: 558-566
• 11 Liu S. The efficacy of self injection premixed insulin in recently diagosed type 2 diabetic outpatients. Chronic Pathematol 2017; 18: 113-115
• 12 Wang P, Lang J, Luo W. et al. The effectiveness and safety of insulin analogues in premixed formulations for newly diagnosed type 2 diabetic out-patient. Modern Hospital 2011; 11: 65-66
• 13 Gao Y. Efficacy of self injection premixed insulin in outpatients with newly diagnosed type 2 diabetes mellitus. China Health Standard Management 2016; 7: 77-78
• 14 Li C. Efficacy of self injection premixed insulin in outpatients with newly diagnosed type 2 diabetes mellitus. Electr J Clin Med Lit. 2019 6. 15–18
• 15 Buse JB, Caprio S, Cefalu WT. et al. How do we define cure of diabetes?. Diabetes Care 2009; 32: 2133-2135
• 16 Gavin JR. New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone 1998; 1: 1-12
• 17 Diabetes society of China Medical Association The prevention and therapy guideline in China type 2 diabetes (2007 edition). Chin J Endocrinol Metab. 2008 24. 2a-1–2a-23
• 18 Geneva. World Health Day 2016 WHO calls for global action to halt rise in and improve care for people with diabetes. WHO; 2016
• 19 Yang W, Lu J, Weng J. et al. Prevalence of diabetes among men and women in China. N Eng J Med 2010; 362: 1090-1101
• 20 King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431
• 21 Ilkova H, Glaser B, Tunckale A. et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356
• 22 Chen A, Huang Z, Wan X. et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012; 35: 474-481
• 23 Liu J, Fang D, Liu L. et al. Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients. Endocr J 2013; 60: 725-732
• 24 Zhang B, Chen YY, Yang ZJ. et al. Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission. J Int Med Res 2016; 44: 1543-1550
• 25 Liu L, Wan X, Liu J. et al. Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol Therap 2012; 14: 756-761
• 26 Kramer CK, Zinman B, Choi H. et al. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Res Care 2016; 4: e000270
• 27 Xu W, Li YB, Deng WP. et al. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chin Med J 2009; 122: 2554-2559
• 28 Huang Z, Wan X, Liu J. et al. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant alpha-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Therap 2013; 15: 859-869
• 29 Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032
• 30 Hu Y, Li L, Xu Y. et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes Care 2011; 34: 1848-1853
• 31 Li Y, Xu W, Liao Z. et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27: 2597-2602 Rheumazentrum Erding, Erding, Germany